We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mersana Therapeutics Inc | NASDAQ:MRSN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.08 | -3.33% | 2.32 | 2.32 | 2.56 | 2.53 | 2.325 | 2.45 | 669,923 | 01:00:00 |
From Jun 2023 to Jun 2024
By Rob Curran
Biotech company Mersana Therapeutics said the Food and Drug Administration lifted a clinical hold on a Phase 1 trial of one of its cancer-treatment candidates.
In March, Mersana said the Food and Drug Administration had issued a clinical hold on the early-stage trial of the gastric-cancer drug candidate because of serious adverse effects.
Based on a review of data, Mersana lowered the starting dose in the Phase 1 dose escalation design, the company said.
In July, Mersana Therapeutics launched a broad restructuring following the failure of its lead product candidate in a late-stage study.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
October 31, 2023 08:52 ET (12:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Mersana Therapeutics Chart |
1 Month Mersana Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
